**News from Renishaw**

*July 2014 – for immediate release. Further information: Chris Pockett, +44 (0) 1453 524133*

**Renishaw *neuromate*® robot upgrade installation in Milan, Italy**

Renishaw is pleased to announce that the world leading ‘Claudio Munari Centre for Epilepsy and Parkinson surgery’ at Niguarda Hospital in Milan, Italy, has upgraded to the newest model of the *neuromate* stereotactic robotic system. This centre specialises in the treatment of epilepsy and has used the *neuromate* system for many years.

Dr. Giorgio Lo Russo, Director of the Centre said, “The *neuromate* system is an integral part of our surgical workflow for invasive recordings with Stereo EEG, indispensable for the diagnosis of MRI-negative epilepsy patient. We are pleased to be equipped with the latest technology available to the benefit of our patients.”

Mr. Paul Skinner, Head of Operations and R&D at Renishaw’s Neurological Products Division added, “This upgrade installation confirms the trust of one of the leading neurosurgical centres in the *neuromate* system and in Renishaw. Niguarda Hospital is one of the key centres providing us with surgeon input for our software and hardware research and development. This type of collaboration with leading clinicians is an integral part of our strategy of developing solutions for the future.”

- ENDS –

Notes to editors

Renishaw is a global company with core skills in measurement, motion control, spectroscopy, neurosurgical products and precision machining. The company has 3,400 employees based at offices in 32 countries, and is listed on the London Stock Exchange (LSE:RSW) where it is a constituent of the FTSE 250.

For more information visit [www.renishaw.com](http://www.renishaw.com)